Literature DB >> 27837337

Public confidence in ADR identification and their views on ADRreporting: mixed methods study.

Narumol Jarernsiripornkul1, Arunrot Patsuree2, Janet Krska3.   

Abstract

PURPOSE: The value of patients as potential reporters into pharmacovigilance systems is acknowledged worldwide and allowed in Thailand. However, nothing is known about the Thai public's awareness of direct patient reporting facility or their views concerning it. This study aimed to determine confidence among members of the public in identifying suspected adverse drug reactions (ADRs), information sources they use and their views towards direct ADR reporting.
METHODS: Mixed methods study consisting of self-administered questionnaires (phase 1) and semi-structured, face-to-face interviews (phase 2) with members of the public recruited in primary care centres, pharmacies and public places during October 2013 to February 2015. All questionnaire respondents reporting an ADR were invited to participate in phase 2. Written informed consent was made before the start of the interview.
RESULTS: There were 414 (17.2%) of 2400 questionnaire respondents who had experienced an ADR, almost half (46%) of whom used their own experience to identify ADRs. Having a degree, having a severe ADR and consulting a physician increased respondent confidence in the association between medicine and suspected ADR. The majority (27) of the 30 interviewees indicated general agreement with patient reporting to regulatory authorities. Four main themes emerged covering reasons for reporting ADRs including expectations of health authorities, healthcare professionals and manufacturers, and helping other people. Awareness of direct reporting was low with a desire for a range of reporting methods.
CONCLUSION: Results indicate support among the Thai general public of direct ADR reporting. Greater promotion of direct reporting by all healthcare professionals is required.

Entities:  

Keywords:  ADR identification; ADR reporting; Adverse drug reactions; Mixed methods; Public’s confidence

Mesh:

Year:  2016        PMID: 27837337     DOI: 10.1007/s00228-016-2155-5

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

Review 1.  Experiences with adverse drug reaction reporting by patients: an 11-country survey.

Authors:  Florence van Hunsel; Linda Härmark; Shanthi Pal; Sten Olsson; Kees van Grootheest
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

2.  Experiences relating to adverse drug reactions in the community: a cross-sectional survey among patients and the general public in Thailand.

Authors:  Arunrot Patsuree; Janet Krska; Narumol Jarernsiripornkul
Journal:  Expert Opin Drug Saf       Date:  2016-01-09       Impact factor: 4.250

3.  Medicine safety: experiences and perceptions of the general public in Liverpool.

Authors:  Janet Krska; Laura Jones; Jonathan McKinney; Craig Wilson
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-08-02       Impact factor: 2.890

4.  A patient's perspective: the impact of adverse drug reactions on patients and their views on reporting.

Authors:  S Lorimer; A Cox; N J Langford
Journal:  J Clin Pharm Ther       Date:  2011-05-18       Impact factor: 2.512

5.  Survey of patients' experiences and their certainty of suspected adverse drug reactions.

Authors:  Jarernsiripornkul Narumol; Patsuree Arunrot; Janet Krska
Journal:  Int J Clin Pharm       Date:  2015-01-10

6.  Adverse drug reaction reporting by patients in the Netherlands: three years of experience.

Authors:  Joyce de Langen; Florence van Hunsel; Anneke Passier; Lolkje de Jong-van den Berg; Kees van Grootheest
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

7.  A qualitative study to explore how patients identify and assess symptoms as adverse drug reactions.

Authors:  Nataporn Chaipichit; Janet Krska; Thongchai Pratipanawatr; Verawan Uchaipichat; Narumol Jarernsiripornkul
Journal:  Eur J Clin Pharmacol       Date:  2014-02-16       Impact factor: 2.953

Review 8.  Under-reporting of adverse drug reactions : a systematic review.

Authors:  Lorna Hazell; Saad A W Shakir
Journal:  Drug Saf       Date:  2006       Impact factor: 5.228

9.  Motives for reporting adverse drug reactions by patient-reporters in the Netherlands.

Authors:  Florence van Hunsel; Christine van der Welle; Anneke Passier; Eugène van Puijenbroek; Kees van Grootheest
Journal:  Eur J Clin Pharmacol       Date:  2010-07-24       Impact factor: 2.953

10.  Patients views and experiences in online reporting adverse drug reactions: findings of a national pilot study in Japan.

Authors:  Michiko Yamamoto; Kiyoshi Kubota; Mitsuhiro Okazaki; Akira Dobashi; Masayuki Hashiguchi; Hirohisa Doi; Machi Suka; Mayumi Mochizuki
Journal:  Patient Prefer Adherence       Date:  2015-01-23       Impact factor: 2.711

View more
  4 in total

1.  A cross-sectional study: comparison of public perceptions of adverse drug reaction reporting and monitoring in eastern and western China.

Authors:  Ningsheng Wang; Yue Chen; Biqi Ren; Yufang Xiang; Nan Zhao; Xianyan Zhan; Bianling Feng
Journal:  BMC Health Serv Res       Date:  2022-03-08       Impact factor: 2.655

2.  Consumer opinions on adverse events associated with medicines and vaccines.

Authors:  Parisa Aslani; Kim Hamrosi; Vivien Tong; Timothy F Chen; Jane Cook; Romano Fois; Theresa McGarry; Carter Moore; Rodney Peters; Sarah Spagnardi; Karen Whitelock
Journal:  Patient Prefer Adherence       Date:  2018-07-31       Impact factor: 2.711

3.  Qualitative Study of General Public Views towards Adverse Drug Reactions in Lithuania.

Authors:  Agne Valinciute-Jankauskiene; Kubiliene Loreta
Journal:  Healthcare (Basel)       Date:  2021-03-09

4.  Motives to Report Adverse Drug Reactions to the National Agency: A Survey Study among Healthcare Professionals and Patients in Croatia, The Netherlands, and the UK.

Authors:  Sieta T de Vries; Petra Denig; Adriana Andrić; Marina Dimov Di Giusti; Alicia Ptaszynska-Neophytou; Linda Härmark; Peter G M Mol
Journal:  Drug Saf       Date:  2021-08-08       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.